College of Veterinary Medicine - Cornell University

Kelly R. Hume, DVM, DACVIM (Oncology)

Diplomate - American College of Veterinary Internal Medicine

Assistant Professor, Section of Oncology
Adjunct Assistant Professor, Biomedical Sciences

CLINICAL TRIALS FOR CATS

Study title: DNA damage response mechanisms and chemosensitivity of feline injection site sarcomas

• Inclusion criteria: Cats suspected of having injection site sarcoma based on location and cytological evaluation (tumors may be primary, recurrent, or metastatic).
  
  
• Purpose: Determine whether alterations in DNA damage response mechanisms impact whether or not a given tumor is susceptible to chemotherapy. This study involves collection of tumor biopsies and in vitro laboratory analysis of those biopsies.
  
  
•  Benefit: Study pays for pre-anesthetic bloodwork, three-view thoracic radiographs, biopsy procedure and associated anesthesia and histopathology charges.
  
  

For additional information, please contact Dr. Kelly Hume or Dr. Cheryl Balkman of the Cornell University Hospital for Animals Oncology Service at 607-253-3060.


Study title: Individualized dosing of carboplatin in cats with injection site sarcomas

• Inclusion criteria: Cats with histological confirmation of tumor type and a measurable primary tumor or metastatic lesion.
  
  
• Purpose: Determine the response rate and toxicity of carboplatin treatment (dosage based on GFR) in cats with injection site sarcomas. It is hypothesized that individualized dosing of carboplatin based on kidney function will be effective and well tolerated.
  
  
• Benefit: Study pays for cost of GFR, two carboplatin treatments, and CBC monitoring after treatment.
  
  

For additional information, please contact Dr. Kelly Hume or Dr. Cheryl Balkman of the Cornell University Hospital for Animals Oncology Service at 607-253-3060.

---

CLINICIAL TRIALS FOR DOGS

Study title: A pilot study to determine if Palladia^™induces hypothyroidism in dogs.

Inclusion criteria: Dogs that are going to receive Palladia™ as part of their anti-cancer treatment.

Exclusion criteria: Dogs that have thyroid carcinoma, dogs that have received neck irradiation, dogs that have life-threatening systemic illness, and/or dogs that are not expected to survive longer than 3 months. 

Purpose: To determine whether Palladia^™ induces hypothyroidism in dogs and to assess the mechanism of this phenomenon.

Benefit: Study pays for a 3 month supply of Palladia^™ and for tests associated with monitoring thyroid gland function.

For additional information, please contact Dr. Vanessa Rizzo, Dr. Kelly Hume, or Dr. Cheryl Balkman of the Cornell University Hospital for Animals Oncology Service at 607-253-3060.